Targacept, Inc. Announces Plans to Develop TC-5214 in Overactive Bladder

Published: Sep 05, 2012

WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics ™, today announced that it plans to pursue development of TC-5214 as a treatment for overactive bladder (OAB). Based on TC-5214’s unique pharmacokinetic profile, an analysis of data from a completed clinical program and findings from additional preclinical studies, the company plans to initiate a Phase 2b study of TC-5214 in the first half of 2013.

Back to news